Introduction
In 1986 Murry and co-workers introduced the term w x 'Ischemic Preconditioning' 1 . In this classical paper the authors referred to ischemic preconditioning as an adaptation to ischemic stress induced by repetitive short periods of ischemia and reperfusion. The protective effect comprised a reduction of energy consumption and a delay of the onset of lethal cell injury during ischemia resulting in a limitation of infarct size after 40 minutes, but not after w x three hours of sustained ischemia 1 . The fascination for this intrinsic protective property of the myocardium has led to a still expanding gamut of research, which was comprehensively reviewed by Yellon and co-workers in w x this issue of CardioÕascular Research 2 .
Three aspects can be distinguished in the process of Ž . ischemic preconditioning. The initial trigger 1 , that is included in the short periods of ischemia and reperfusion, Ž . activates signalling pathways 2 , which in their turn act upon an end-effector inducing the delay of lethal ischemic Ž . damage during sustained ischemia 3 . All three facets have been extensively studied, although the vast majority of the investigations focuses on the signalling pathways. In spite of this, the central mechanism, which results in the delay of necrosis, remains unclear. Therefore, it can be questioned whether the apparently centrifugal expansion of triggers, mediators and salutary endpoints of ischemic w x preconditioning 2,3 will at any time lead us to clarify a central effector mechanism. This paper aims at expounding the concept of the central mechanism and critically reviews the still increasing number of proposed signalling pathways and salutary endpoints of preconditioning.
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The trigger of ischemic preconditioning
Obviously, the factor initiating protection is operative during the short periods of ischemia or reperfusion of ischemic preconditioning. However, this factor remains obscure. The majority of evidence suggests that it is the ischemia and not the reperfusion that starts the preconditioning cascade. Schulz and co-workers showed that a 10-min period of no-flow ischemia provides protection against subsequent low-flow ischemia without intermittent w x reperfusion 4 . Since adenosine is produced by degradation of ATP during the short periods of ischemia and activates a protective cascade when administered, it has been proposed as a trigger for ischemic preconditioning w x w x 5 . Also, bradykinin may act as a trigger 6 . However, several observations mitigate the importance of adenosine and bradykinin in triggering preconditioning. Adenosine and bradykinin are not important for preconditioning in w x rats 7,8 . Also, hypoxic perfusion, preventing extracellular accumulation of adenosine is as effective as ischemia in w x inducing preconditioning 9 . Moreover, antagonizing the bradykinin B receptor does not prevent cardioprotection 2 after 4 cycles of short periods of ischemia and reperfusion w x in rabbit hearts 6 .
An alternative candidate for initiating ischemic preconditioning is a preischemic mild increase of the intracellular If the intensity of the preconditioning stimulus exceeds a certain threshold by extending or frequently repeating the w x period of ischemia, the protective effect is lost 15 . Other 'subthreshold' noxious interventions, including hypoxia w x w x w 2q x w x 9 , stretch 16 and a mild increase of Ca 13 , also i initiate a protective effect and may share a common stimulus with ischemic preconditioning. However, such comparison does not stand up for preconditioning the myocardium with drugs. In pharmacological preconditioning the period of drug treatment is in principle separated from the start of ischemia by a drug free episode. However, it has never been clarified whether the drugs are completely washed w x out prior to ischemia 17 . In any case, a drug-free interval in pharmacological preconditioning is not a prerequisite for protection, in contrast to a period of reperfusion in ischemic preconditioning. Therefore, pharmacological preconditioning might not be helpful to elucidate the trigger and initial steps of the mechanism underlying ischemic preconditioning. Instead, detailed biochemical analysis of myocardium during periods of ischemia and reperfusion may provide the key to the understanding of ischemic w x preconditioning 18 .
The endpoint of ischemic preconditioning
The classical endpoint of preconditioning is the delay of lethal injury reducing infarct size during a temporary w x coronary occlusion 1 . In line with these initial observations various studies have demonstrated that specific manifestations of the onset of ischemic myocardial necrosis are w 2q x postponed by preconditioning. The terminal rise in Ca i w x is delayed by ischemic preconditioning 18-20 . Also, the development of ischemia-induced ultrastructural damage is w x slowed by preconditioning 21 . The delay of the onset of ischemia-induced electrical uncoupling is another manifestation of protection against ischemic damage by precondiw x tioning 20,22,23 . However, reports in the literature about the effect of preconditioning on the start of contracture are conflicting, probably depending on differences in species and experimental models. Studies in both rat and rabbit w x hearts 20,24,25 show that preconditioning postpones the start of contracture during sustained ischemia compared to control hearts. Opposite results showing that preconditioning advances ischemia-induced contracture during sustained ischemia have been obtained exclusively in rats w x 26,27 . This discrepancy is surprising, since preconditioning delays the development of necrosis, while contracture is strongly indicative of irreversible ischemic damage and w x necrosis 28 .
Several salutary endpoints have been described in addition to the delay of lethal ischemic damage and infarct size reduction. However, compelling evidence is currently lacking to conclude that these endpoints comprise different signalling pathways and different mechanisms. Therefore, there is no ground to renounce that the delay of ischemic damage is the common basis of all parameters of cardioprotection.
Infarct size reduction
Infarct size reduction is the prevailing measure of cardioprotection. The transmural progression of the infarct from endocardium to epicardium during acute myocardial w x w x ischemia 29 is not interrupted, yet merely retarded 21 . Therefore, infarct size reduction is lost when sustained ischemia is extended to three hours, as already noted in the w x first paper on preconditioning 1 . In short, 'infarct size reduction' after a temporary coronary occlusion is a consequence of the delay of ischemic cell death.
Antiarrhythmic effects
A preconditioning-induced reduction of the incidence and severity of arrhythmias during ischemia and reperfuw x sion has been described primarily in rats 30-32 , but also w x in dogs and humans 33,34 . Other studies in pigs and dogs have demonstrated an absent or stimulating effect of prew x conditioning on the occurrence of arrhythmias 1,35 .
It is premature to conclude that the reduced incidence of arrhythmias by preconditioning is due to an antiarrhythmic effect per se and not to the 'classical' delay of ischemic cell death. The rat is not a representative model to study ischemia-induced arrhythmias. The action potential characteristics of rat ventricle, and their changes during ischemia, are different compared to larger mammals. Furthermore, the small size of rat hearts probably precludes the division of ischemia-induced arrhythmias into the phase 1a and 1b arrhythmias, which normally occur in larger hearts and have been shown to depend on different arrhythmogenic w x mechanisms 36,37 .
As infarct size by itself is an important determinant of the incidence and severity of ventricular arrhythmias w x 38,39 , the reduction of the incidence of arrhythmias in preconditioned myocardium is, at least partially, caused by w x the limitation of infarct size during early ischemia 40 . Therefore, equal infarct sizes between control and preconditioned groups are mandatory to decide whether preconditioning has a true antiarrhythmic effect.
The electrophysiological derangements underlying phase 1a and 1b arrhythmias during ischemia, such as ST-segment elevation and electrical cellular uncoupling, are attenuated and postponed after preconditioning, respectively w x 20,22,41 . Accordingly, Cinca and co-workers recently showed that ischemic preconditioning postpones electrical uncoupling as well as the 1b phase of arrhythmias during w x sustained ischemia in pigs 23 . The slowing of the ischemic changes and the reduction of the size of the infarcted area underlie the reduced propensity of preconditioned myocardium to arrhythmias during ischemia and reperfusion. 
Reduction of contractile dysfunction
It has been demonstrated in many species that ischemic preconditioning attenuates postischemic myocardial conw x tractile dysfunction 26,27,42 . This beneficial effect is not caused by a reduction of stunning, because preconditioning w x does not protect against stunning 43, 44 . Improvement of postischemic function by preconditioning is secondary to the delay of ischemic myocardial damage, because parameters of the degree of necrosis, such as infarct size and enzyme leakage, correlate with the enhancement of funcw x tional recovery 42,43 .
Clinical applications
Although ischemic preconditioning might occur under Ž certain clinical conditions for review see Verdouw and w x. co-workers 45 , this does not mean that it constitutes a w x promising tool for daily clinical practice 46 . Recent experimental investigations have demonstrated that in myocardium affected by certain preexisting pathological conditions ischemic preconditioning does not have its desired effects. In aging rat hearts the beneficial effects of preconw x ditioning are lost or reversed 47,48 . Furthermore, we have recently shown that in hearts from rabbits suffering from severe heart failure preconditioning may paradoxically advance markers of the onset of ischemic damage w x 49 .
Signalling pathways of ischemic preconditioning
In contrast to the scant knowledge about the mechanisms underlying the initiating event and the endpoint of ischemic preconditioning, the potential signalling pathways have been, and continue to be, extensively studied. Unfortunately, the interrelations between the stimulus, the intracellular transduction pathways and the final effector mechanism remain unknown at present.
A adenosine receptor 1
In addition to its role as a trigger, it has also been suggested that adenosine receptor binding acts as a mediaw x tor of preconditioning 5 . Protective effects after activation of the A adenosine receptor have been described in 
Protein kinase C
It has been proposed that activation of G protein coupled receptors, including a adrenergic, A adenosine, 1B 1 muscarinic and endothelin receptors, plays an important role in ischemic preconditioning by inducing a translocaw x tion of PKC to the membrane 2,60-64 . However, downstream of this point in the supposed PKC-mediated pathway of preconditioning information and even hypotheses are lacking at present.
As with the other mediators, the role of the non-selective second messenger PKC in preconditioning has become w x subject to considerable controversy 65 . Several recent publications, in which PKC inhibition did not prevent w x cardioprotection 66,67 , or even induced an additional w x protective effect 68 , seriously dispute the role of PKC in preconditioning. A confounding factor in examining the effects of PKC is the existence of at least 6 isoforms with w x their own characteristics in cardiac tissue 69 . To date, the relative roles of these isoforms in the protective effect of preconditioning, if any, are unclear.
Other possible mechanisms
Other mechanisms, that will not be discussed in further Ž w x. detail for review see 2,3 have been proposed. Arachiw x w x w x donic acid 19 , stretch 16 , heat stress proteins 70 and w x Ž . mitogen-activated protein kinases 71 MAP kinases have all been associated with preconditioning.
Attempts have been made to unify some of the aspects of the apparently diverging field of triggers and mediators in preconditioning. For instance, one possible effector mechanism of the A adenosine receptors is the activation 1 of ATP-sensitive K q channels via a G protein mediated i w x process 52,72 . Alternatively, a synergistic modulation of K channels by PKC and adenosine has been described ATP ( )w x 53 . However, in view of the still expanding list of triggers and mediators, it is possible that all these mechanisms converge into an as yet unidentified final common pathway. The vast majority of the above studies applied pharmacological interventions that either block, stimulate or mimic the pathway of interest. These drug interventions, however, are fraught with nonspecific, largely unknown side effects. A striking example is the widely used PKC inhibitor polymyxin B, that, apart from a low specificity w x for PKC, also inhibits the K channel 73 . Therefore, ATP studies that apply pharmacological means to investigate mediators of ischemic preconditioning should be interpreted with caution.
The mechanism of the delay of ischemic damage
The common feature characterizing the protected state of preconditioned myocardium is a reduction of energy demand causing a delay of necrosis during sustained isw x chemia 21 . Although preconditioning reduces mitochondrial ATP by about 30%, the rate of decline during subsequent sustained ischemia is decreased and only after 15 minutes of ischemia ATP content in preconditioned and w x control hearts is similar 18,21,74 . As glycogen utilization is depressed after preconditioning, the slower rate of high energy phosphate depletion during sustained ischemia can only be a consequence of a reduced energy consumption during ischemia in preconditioned myocardium compared w x to ischemia in control myocardium 18,21,75 . Murry and co-workers proposed that this initial reduced rate of anaerobic glycolysis attenuates the accumulation of glycolytic products, including lactate, and that this could be responsiw x ble for delaying cell death 21 . In support of this idea are studies showing that preconditioning slows the developw x ment of acidosis during sustained ischemia 18, 26,75 . A pivotal hiatus in the understanding of preconditioning is that the fundamental central mechanism underlying the reduction of energy consumption and the delay of necrosis during sustained ischemia remains unclear. Attenuation of contractile function by the brief periods of ischemia and Ž . reperfusion 'stunning' does not underlie decreased energy consumption in preconditioning. Murry and coworkers have shown that the protective effect of a 15-min period of preconditioning ischemia is lost after 120 min, whereas stunning is still present indicating that the time w x windows of protection and stunning are different 76 . Furthermore, eluding stunning, via hypoxic preconditioning or administration of dobutamine, does not prevent w x protection 77,78 . Another important pathway consuming energy during early ischemia is the reversal of the mitochondrial ATPase. However, this also does not play a role in the energy sparing effect of ischemic preconditioning, since ATP hydrolysis by the mitochondrial ATPase during ischemia is inhibited within the first 90 s of ischemia in w x control and preconditioned cardiac tissue 79 .
In pharmacological preconditioning the drug-free interval is not essential for the protective effect, in contrast to Ž the period of reperfusion in ischemic preconditioning see . above . Therefore, one should ponder on the question whether the mechanisms underlying the protective effects of pharmacological preconditioning are essentially different from the long-established increase of ischemic tolerance by preischemic treatment with agents like propranolol w x or verapamil 80,81 . Moreover, these considerations also indicate that it is not self-evident that mechanisms underlying pharmacological preconditioning can be extrapolated to ischemic preconditioning.
It is tempting to speculate on a novel common mechaw 2q x nism of ischemic preconditioning. from the SR into the cytosol may constitute a positive feedback loop resulting in a thermodynamically favorable and protected status of the myocardium.
In conclusion, ischemic preconditioning definitely is a powerful means to protect the ischemic myocardium. However, current research on the different aspects of preconditioning seems to diverge more and more. Although this provides numerous interesting new data, the central mechanism of ischemic preconditioning remains obscure. Furthermore, pharmacological preconditioning is not necessarily an analog of ischemic preconditioning. Therefore, this paper is meant as an impetus to focus on the basic and essential factors of cell death and the reduction of energy consumption during ischemia. 
